Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 1/2016

01-01-2016 | Review

Cutaneous immunology: basics and new concepts

Authors: Amir S. Yazdi, Martin Röcken, Kamran Ghoreschi

Published in: Seminars in Immunopathology | Issue 1/2016

Login to get access

Abstract

As one of the largest organs, the skin forms a mechanical and immunological barrier to the environment. The skin immune system harbors cells of the innate immune system and cells of the adaptive immune system. Signals of the innate immune system typically initiate skin immune responses, while cells and cytokines of the adaptive immune system perpetuate the inflammation. Skin immune responses ensure effective host defense against pathogens but can also cause inflammatory skin diseases. An extensive crosstalk between the different cell types of the immune system, tissue cells, and pathogens is responsible for the complexity of skin immune reactions. Here we summarize the major cellular and molecular components of the innate and adaptive skin immune system.
Literature
1.
Adachi O, Kawai T, Takeda K et al (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9:143–150PubMedCrossRef
2.
3.
Allan RS, Smith CM, Belz GT et al (2003) Epidermal viral immunity induced by CD8alpha + dendritic cells but not by Langerhans cells. Science 301:1925–1928PubMedCrossRef
4.
Asadullah K, Friedrich M, Hanneken S et al (2001) Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J Invest Dermatol 116:721–727PubMedCrossRef
5.
Benson JM, Sachs CW, Treacy G et al (2011) Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol 29:615–624PubMedCrossRef
6.
Biedermann T, Kneilling M, Mailhammer R et al (2000) Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 192:1441–1452PubMedPubMedCentralCrossRef
7.
Biedermann T, Mailhammer R, Mai A et al (2001) Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells. Eur J Immunol 31:1582–1591PubMedCrossRef
8.
Biedermann T, Zimmermann S, Himmelrich H et al (2001) IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2:1054–1060PubMedCrossRef
9.
Bissonnette R, Poulin Y, Guenther L et al (2011) Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 25:1402–1408PubMedCrossRef
10.
Braumuller H, Wieder T, Brenner E et al (2013) T-helper-1-cell cytokines drive cancer into senescence. Nature 494:361–365PubMedCrossRef
11.
12.
Canna SW, De Jesus AA, Gouni S et al (2014) An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46:1140–1146PubMedPubMedCentralCrossRef
13.
Chiu HY, Huang HL, Li CH et al (2015) Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. Br J Dermatol 173:146–154PubMedCrossRef
14.
Christophers E, Metzler G, Rocken M (2014) Bimodal immune activation in psoriasis. Br J Dermatol 170:59–65PubMedCrossRef
15.
Dombrowski Y, Peric M, Koglin S et al (2011) Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med 3:82ra38PubMedPubMedCentralCrossRef
16.
Drexler SK, Bonsignore L, Masin M et al (2012) Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci U S A 109:18384–18389PubMedPubMedCentralCrossRef
17.
Duhen T, Geiger R, Jarrossay D et al (2009) Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 10:857–863PubMedCrossRef
18.
Feldmeyer L, Keller M, Niklaus G et al (2007) The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol 17:1140–1145PubMedCrossRef
19.
Fink SL, Cookson BT (2006) Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol 8:1812–1825PubMedCrossRef
20.
Gagliani N, Vesely MC, Iseppon A et al (2015) Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 523:221–225PubMedPubMedCentralCrossRef
21.
Ghoreschi K, Thomas P, Breit S et al (2003) Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 9:40–46PubMedCrossRef
22.
23.
24.
Gomez De Aguero M, Vocanson M, Hacini-Rachinel F et al (2012) Langerhans cells protect from allergic contact dermatitis in mice by tolerizing CD8(+) T cells and activating Foxp3(+) regulatory T cells. J Clin Invest 122:1700–1711PubMedPubMedCentralCrossRef
25.
Gordon KB, Langley RG, Gottlieb AB et al (2012) A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 132:304–314PubMedCrossRef
26.
Grewe M, Gyufko K, Schopf E et al (1994) Lesional expression of interferon-gamma in atopic eczema. Lancet 343:25–26PubMedCrossRef
27.
Griffiths CE, Strober BE, Van De Kerkhof P et al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118–128PubMedCrossRef
28.
Gross O, Yazdi AS, Thomas CJ et al (2012) Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 36:388–400PubMedCrossRef
29.
Guenova E, Skabytska Y, Hoetzenecker W et al (2015) IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci U S A 112:2163–2168PubMedPubMedCentralCrossRef
30.
Harbour SN, Maynard CL, Zindl CL et al (2015) Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proc Natl Acad Sci U S A 112:7061–7066PubMedPubMedCentralCrossRef
31.
Hauschild A, Weichenthal M, Rass K et al (2010) Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol 28:841–846PubMedCrossRef
32.
Hauser C, Katz SI (1988) Activation and expansion of hapten- and protein-specific T helper cells from nonsensitized mice. Proc Natl Acad Sci U S A 85:5625–5628PubMedPubMedCentralCrossRef
33.
Hauser C, Yokoyama WM, Katz SI (1989) Characterization of primary T helper cell activation and T helper cell lines stimulated by hapten-modified, cultured Langerhans cells. J Invest Dermatol 93:649–655PubMedCrossRef
34.
Heath WR, Carbone FR (2009) Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 10:1237–1244PubMedCrossRef
35.
Hirahara K, Ghoreschi K, Laurence A et al (2012) Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev 21:425–434CrossRef
36.
Hoffman HM, Mueller JL, Broide DH et al (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29:301–305PubMedPubMedCentralCrossRef
37.
38.
Jakob T, Saitoh A, Udey MC (1997) E-cadherin-mediated adhesion involving Langerhans cell-like dendritic cells expanded from murine fetal skin. J Immunol 159:2693–2701PubMed
39.
Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373–384PubMedCrossRef
40.
Kopp T, Riedl E, Bangert C et al (2015) Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 521:222–226PubMedCrossRef
41.
Langley RG, Lebwohl M, Krueger GG et al (2015) Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol 172:1371–1383PubMedCrossRef
42.
Lauterbach H, Bathke B, Gilles S et al (2010) Mouse CD8alpha + DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med 207:2703–2717PubMedPubMedCentralCrossRef
43.
Lee HH, Song IH, Friedrich M et al (2007) Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 156:486–491PubMedCrossRef
44.
Leonardi C, Matheson R, Zachariae C et al (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366:1190–1199PubMedCrossRef
45.
Li P, Allen H, Banerjee S et al (1995) Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80:401–411PubMedCrossRef
46.
Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308:898–908PubMedCrossRef
47.
Luckey U, Schmidt T, Pfender N et al (2012) Crosstalk of regulatory T cells and tolerogenic dendritic cells prevents contact allergy in subjects with low zone tolerance. J Allergy Clin Immunol 130(781–797):e711
48.
Malissen B, Tamoutounour S, Henri S (2014) The origins and functions of dendritic cells and macrophages in the skin. Nat Rev Immunol 14:417–428PubMedCrossRef
49.
Mariathasan S, Weiss DS, Newton K et al (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228–232PubMedCrossRef
50.
Mocikat R, Braumuller H, Gumy A et al (2003) Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19:561–569PubMedCrossRef
51.
52.
Pasparakis M, Haase I, Nestle FO (2014) Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol 14:289–301PubMedCrossRef
53.
Reich K, Nestle FO, Papp K et al (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367–1374PubMedCrossRef
54.
Reich K, Langley RG, Papp KA et al (2011) A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 365:1586–1596PubMedCrossRef
55.
Rocken M, Muller KM, Saurat JH et al (1992) Central role for TCR/CD3 ligation in the differentiation of CD4+ T cells toward A Th1 or Th2 functional phenotype. J Immunol 148:47–54PubMed
56.
Rocken M, Saurat JH, Hauser C (1992) A common precursor for CD4+ T cells producing IL-2 or IL-4. J Immunol 148:1031–1036PubMed
57.
58.
Salmon-Ceron D, Tubach F, Lortholary O et al (2011) Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70:616–623PubMedCrossRef
59.
60.
Singh JA, Cameron C, Noorbaloochi S et al (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386:258–265PubMedCrossRef
61.
Skabytska Y, Wolbing F, Gunther C et al (2014) Cutaneous innate immune sensing of Toll-like receptor 2–6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity 41:762–775PubMedCrossRef
62.
Sollberger G, Strittmatter GE, Grossi S et al (2015) Caspase-1 activity is required for UVB-induced apoptosis of human keratinocytes. J Invest Dermatol 135:1395–1404PubMedCrossRef
63.
Staehli F, Ludigs K, Heinz LX et al (2012) NLRC5 deficiency selectively impairs MHC class I-dependent lymphocyte killing by cytotoxic T cells. J Immunol 188:3820–3828PubMedCrossRef
64.
Tattoli I, Travassos LH, Carneiro LA et al (2007) The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation. Semin Immunopathol 29:289–301PubMedCrossRef
65.
Thornberry NA, Bull HG, Calaycay JR et al (1992) A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356:768–774PubMedCrossRef
66.
Villanova F, Flutter B, Tosi I et al (2014) Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol 134:984–991PubMedPubMedCentralCrossRef
67.
Wollenberg A, Kraft S, Hanau D et al (1996) Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 106:446–453PubMedCrossRef
68.
Yang XP, Ghoreschi K, Steward-Tharp SM et al (2011) Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12:247–254PubMedPubMedCentralCrossRef
69.
Yao C, Zurawski SM, Jarrett ES et al. (2015) Skin dendritic cells induce follicular helper T cells and protective humoral immune responses. J Allergy Clin Immunol
70.
Yazdi AS, Guarda G, Riteau N et al (2010) Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL-1beta. Proc Natl Acad Sci U S A 107:19449–19454PubMedPubMedCentralCrossRef
71.
Zimmermann S, Egeter O, Hausmann S et al (1998) CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 160:3627–3630PubMed
72.
Metadata
Title
Cutaneous immunology: basics and new concepts
Authors
Amir S. Yazdi
Martin Röcken
Kamran Ghoreschi
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 1/2016
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-015-0545-x

Other articles of this Issue 1/2016

Seminars in Immunopathology 1/2016 Go to the issue

Review

The role of innate immune signaling in the pathogenesis of atopic dermatitis and consequences for treatments

Review

Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy

Review

Lupus erythematosus revisited

Review

Adverse cutaneous drug eruptions: current understanding

Review

Cutaneous dermatomyositis in the era of biologicals

Introduction

The skin and its blossoms—fertile soil for clinical science
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits